AU7442398A - Glucosamine fatty acid compositions and their use - Google Patents

Glucosamine fatty acid compositions and their use

Info

Publication number
AU7442398A
AU7442398A AU74423/98A AU7442398A AU7442398A AU 7442398 A AU7442398 A AU 7442398A AU 74423/98 A AU74423/98 A AU 74423/98A AU 7442398 A AU7442398 A AU 7442398A AU 7442398 A AU7442398 A AU 7442398A
Authority
AU
Australia
Prior art keywords
fatty acid
acid compositions
glucosamine fatty
glucosamine
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74423/98A
Inventor
David Frederick Horrobin
Mehar Singh Manku
Austin Mcmordie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Publication of AU7442398A publication Critical patent/AU7442398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU74423/98A 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use Abandoned AU7442398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9710351.9A GB9710351D0 (en) 1997-05-20 1997-05-20 Glucosamine fatty acids
GB9710351 1997-05-20
PCT/GB1998/001425 WO1998052556A1 (en) 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use

Publications (1)

Publication Number Publication Date
AU7442398A true AU7442398A (en) 1998-12-11

Family

ID=10812725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74423/98A Abandoned AU7442398A (en) 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use

Country Status (6)

Country Link
EP (1) EP0977561A1 (en)
AU (1) AU7442398A (en)
CA (1) CA2290488A1 (en)
GB (1) GB9710351D0 (en)
WO (1) WO1998052556A1 (en)
ZA (1) ZA984211B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032188A1 (en) * 1999-11-02 2001-05-10 Shawn Paul Madere Compositions of orally administered nutritional supplements to repair articular cartilage
US7214666B1 (en) 1999-11-02 2007-05-08 Shawn Paul Madere Composition of orally administered nutritional supplements to repair articular cartilage
DE10019255A1 (en) * 2000-04-18 2001-10-31 Henkel Kgaa Glycoside esters and their production and use in cosmetics, pharmaceuticals and food or feed
JP2006502213A (en) 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulators
WO2007091070A1 (en) * 2006-02-07 2007-08-16 Universitetet I Oslo Omega 3
DE102007055344A1 (en) 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh New use of omega-3 fatty acid (s)
FR2940281B1 (en) * 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
MX2013007191A (en) * 2010-12-21 2013-07-12 Nestec Sa Methods and compositions for preventing and treating osteoarthritis.
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168003A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammation
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
ES2797624T3 (en) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composition for the treatment of inflammatory bowel disease
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
MA52644A (en) 2014-06-04 2021-03-24 Ds Biopharma Ltd PHARMACEUTICAL COMPOSITIONS CONSISTING OF DGLA ACID AND THEIR USE
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (en) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939813A (en) * 1982-08-26 1984-03-05 Shiseido Co Ltd Cosmetic
WO1993024505A1 (en) * 1992-05-26 1993-12-09 Alberta Research Council Reducing inflammation by time dependent administration of oligosaccharides glycosides related to blood group determinants
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
GB9508023D0 (en) * 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
AU2623797A (en) * 1995-12-11 1997-07-03 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis

Also Published As

Publication number Publication date
WO1998052556A1 (en) 1998-11-26
EP0977561A1 (en) 2000-02-09
GB9710351D0 (en) 1997-07-16
CA2290488A1 (en) 1998-11-26
ZA984211B (en) 1998-11-20

Similar Documents

Publication Publication Date Title
AU7442398A (en) Glucosamine fatty acid compositions and their use
AU4038797A (en) Diagnostic compositions and devices utilizing same
AU6568598A (en) Bioactive sol-gel compositions and methods
AU3542197A (en) Starch-containing cosmetic and cleaning compositions
AU6724598A (en) 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors
AU3986795A (en) Succinic acid derivatives and their use as surfactants
AU2535197A (en) Alteration of amino acid compositions in seeds
AU1348095A (en) Fatty acid derivatives
AU7364498A (en) Non-corrosive stripping and cleaning composition
AU1794997A (en) Cleansing compositions comprising xanthan gum and cross-linked polyacrylic acid
AU1583795A (en) Galactomannan products and compositions containing the same
AU4124997A (en) Fatty acid treatment
AU1919295A (en) Aminophospholipid compositions and uses thereof
AU3671099A (en) Methods and compositions pertaining to pd-loops
AU2215995A (en) Freeze-dried compositions comprising rna
GB9615089D0 (en) Esters and compositions comprising them
AU5935398A (en) Detergent cosmetic compositions and use thereof
AU7968394A (en) Acid cleansing and staining compositions
AU2972597A (en) Compositions and uses thereof
AU9166298A (en) Detergent cosmetic compositions and use
AU1957797A (en) Zwitterionic compositions and methods as biological response modifiers
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
AU5836498A (en) N-acyl-hydroxyamino acid esters and their use
AU4834200A (en) Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
AU9301998A (en) Composition and methods using galectin-1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase